🔬 Mis-pairing of heavy chains creates impurities in manufacturing.
💡 Evitria utilizes Lonza’s bYlok® tech to enhance light chain pairing, leading to better outcomes.
🚀 Early screening expedites process development and reduces impurities, supporting clients in achieving effective bispecifics for clinical applications.
Introduction:
The article discusses advancements in the manufacturing processes of bispecific antibodies (bsAbs), which uniquely combine two different antibodies to create a therapeutic option with dual action. The focus is on addressing common production challenges, particularly concerning the purification and correct pairing of molecular components during synthesis.
- Evitria, a custom antibody manufacturer, is exploring various bispecific antibody designs to optimize performance and reduce impurities.
- The mispairing of heavy chains during bispecific antibody assembly leads to the production of undesired molecules (homodimers), negatively impacting manufacturing yields.
- Evitria has licensed Lonza’s bYlok® technology, which utilizes a “knob-into-holes” strategy to enhance light chain pairing and facilitate correct bonding.
- By evaluating multiple configurations (knob vs. hole formations) of antibodies, efficiency in expression levels and purity can be assessed, thereby improving overall production.
- This early screening process supports clients in optimizing their antibody configurations, thus expediting the transition from development to commercial manufacturing.
Conclusion:
The article highlights significant steps being made in bispecific antibody manufacturing, particularly through innovative strategies that address traditional challenges. By focusing on correct molecular assembly and reducing impurities early in the production process, companies can enhance yield and move more swiftly towards clinical applications. These developments signify a promising future for bispecific antibodies in therapeutic contexts.
